Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab) and to characterize the safety of each RP2D for selected treatment combinations.
Multiple Myeloma
I
Dholaria, Bhagirathbhai
NCT04108195
VICCHEMP1995

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin, and cisplatin to determine the safety and maximum tolerated dose.
Lymphoma, Ovarian, Phase I
I
Berlin, Jordan
NCT02278250
VICCPHI14126

Selinexor and Docetaxel in Treating Participants with Stage IV KRAS Mutant Non-Small Cell Lung Cancer

Multiple Cancer Types

This phase I / II trial studies the safety and best dose of selinexor and docetaxel in treating participants with stage IV KRAS-mutation non-small cell lung cancer that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor and docetaxel may work better in treating participant with stage IV KRAS mutant non-small cell lung cancer.
Lung, Non Small Cell
I/II
York, Sally
NCT03095612
VICCTHO1791

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Lung

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:- - Arm A: Tiragolumab plus atezolizumab and CE - Arm B: Placebo plus atezolizumab and CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).
Lung
III
Iams, Wade
NCT04256421
VICCTHO19137

Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

Breast

This phase IIa trial studies the side effects of atezolizumab when given together with paclitaxel, trastuzumab, and pertuzumab and to see how well it works in treating patients with HER2 positive breast cancer that has come back at or near the same place as the original (primary) tumor (locally recurrent), has spread to other places in the body (metastatic), or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, paclitaxel, trastuzumab, and pertuzumab may work better in treating patients with HER2 positive breast cancer.
Breast
II
Mayer, Ingrid
NCT03125928
VICCBRE18179

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Leukemia

This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA). The FDA allows DS-3201b to be used only in research. It is not known if DS-3201b will work or not. This study consists of two parts. The first part (Part 1) is a dose escalation that will enroll subjects with AML or ALL that did not respond or no longer respond to previous standard therapy. The purpose of Part 1 of this research study is to determine the highest dose a patient can tolerate or recommended dose of DS-3201b that can be given to subjects with AML or ALL. Once the highest tolerable dose is determined, additional subjects will be enrolled at that dose into Part 2 of the study.
Leukemia
I
Oluwole, Olalekan
NCT03110354
VICCHEM1765

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Multiple Cancer Types

The main purpose of the study is to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Lung, Non Small Cell, Phase I
I/II
Iams, Wade
NCT03840915
VICCTHO1920

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Multiple Cancer Types

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.
Colon, Rectal
II
Ciombor, Kristen
NCT04096417
VICCGI2028

Phase 1b / 2 Study of Rivoceranib and Trifluridine / Tipiracil for Metastatic Colorectal Cancer

Multiple Cancer Types

Comparing the efficacy of rivoceranib and trifluridine / tipiracil administered individually as monotherapies, as well as a rivocernib plus trifluridine / tipiracil combination therapy in the treatment of mCRC that is unresponsive to traditional chemotherapies.
Colon, Rectal
I/II
Eng, Cathy
NCT04073615
VICCGI1970

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: